CML-981: A Multinational Study to Explore Patient Preferences for Chronic Myeloid Leukemia Treatments

Clinical Lymphoma Myeloma & Leukemia, vol. 25, pp. S588–S589

Authors 12

1. Priscila Radu

   Office Of Health Economics

   Affiliation as printed

   Office of Health Economics, London, United Kingdom

2. David John Mott

   Office Of Health Economics

   Affiliation as printed

   Office of Health Economics, London, United Kingdom

3. Tim H. Brümmendorf Aachen Department of Hematology and Oncology Faculty of Medicine

   RWTH Aachen University

   Affiliation as printed

   Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany

   Department of Hematology and Oncology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany

4. Denis Costello
   Affiliation as printed

   CML Advocates Network, Bern, Switzerland

5. Anastasia Goussarova
   Affiliation as printed

   CML Advocates Network, Bern, Switzerland

6. Thomas William LeBlanc

   Duke University · Duke Cancer Institute

   Affiliation as printed

   Duke Cancer Institute, Durham, NC, USA

7. Šarūnas Narbutas
   Affiliation as printed

   Lithuanian Cancer Patient Coalition (POLA), Vilnius, Lithuania

8. Mandy Ryan

   University of Aberdeen

   Affiliation as printed

   University of Aberdeen, Aberdeen, United Kingdom

9. Nicole Schroeter
   Affiliation as printed

   Olshan Patient Relations, Munich, Bavaria, Germany

10. Franz Alisch
    Affiliation as printed

    Novartis Pharmaceuticals UK Ltd, London, United Kingdom

11. Mo Zhou
    Affiliation as printed

    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

12. Chris D. Skedgel

    Office Of Health Economics

    Affiliation as printed

    Office of Health Economics, London, United Kingdom